PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 174 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2017. The put-call ratio across all filers is 0.97 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $340,000 | +83.8% | 33,664 | +90.2% | 0.10% | +222.6% |
| Q2 2020 | $185,000 | -87.0% | 17,700 | -89.1% | 0.03% | -76.7% |
| Q4 2019 | $1,419,000 | -58.4% | 162,141 | -48.8% | 0.13% | -54.8% |
| Q3 2019 | $3,407,000 | +1.9% | 316,474 | +20.4% | 0.29% | +12.2% |
| Q2 2019 | $3,342,000 | -16.0% | 262,945 | +34.4% | 0.26% | -15.5% |
| Q4 2018 | $3,980,000 | +430.7% | 195,589 | +2178.0% | 0.31% | +463.6% |
| Q2 2017 | $750,000 | -93.6% | 8,586 | -97.8% | 0.06% | -93.3% |
| Q2 2016 | $11,789,000 | +149.2% | 395,750 | +145.7% | 0.82% | +158.5% |
| Q1 2016 | $4,730,000 | -13.7% | 161,078 | +30.5% | 0.32% | -52.8% |
| Q2 2013 | $5,478,000 | – | 123,473 | – | 0.67% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,792,114 | $4,713,260 | 4.15% |
| Eversept Partners, LP | 1,681,149 | $4,421,422 | 0.37% |
| Camber Capital Management LP | 4,235,000 | $11,138 | 0.37% |
| Kynam Capital Management, LP | 473,975 | $1,246,554 | 0.20% |
| GLOBEFLEX CAPITAL L P | 538,559 | $1,416,410 | 0.17% |
| Affinity Asset Advisors, LLC | 202,349 | $532,178 | 0.15% |
| GSA CAPITAL PARTNERS LLP | 279,629 | $735 | 0.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 363,666 | $956,442 | 0.06% |
| Patriot Financial Group Insurance Agency, LLC | 67,000 | $176,210 | 0.04% |
| ACADIAN ASSET MANAGEMENT LLC | 1,858,000 | $4,884 | 0.02% |